Total Payments
$664,346
2024 Payments
$54,870
Companies
3
Transactions
68
Payment Breakdown by Category
Research$643,504 (96.9%)
Consulting$20,843 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $643,504 | 13 | 96.9% |
| Consulting Fee | $20,843 | 55 | 3.1% |
Payments by Type
Research
$643,504
13 transactions
General
$20,843
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $343,118 | 4 | $0 (2021) |
| Eli Lilly and Company | $300,386 | 9 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $20,843 | 55 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,870 | 2 | Eli Lilly and Company ($54,870) |
| 2023 | $143,355 | 2 | Eli Lilly and Company ($143,355) |
| 2022 | $100,736 | 2 | Eli Lilly and Company ($100,736) |
| 2021 | $44,348 | 22 | E.R. Squibb & Sons, L.L.C. ($37,088) |
| 2020 | $57,775 | 17 | E.R. Squibb & Sons, L.L.C. ($53,950) |
| 2019 | $254,495 | 12 | E.R. Squibb & Sons, L.L.C. ($251,730) |
| 2018 | $2,220 | 5 | Merck Sharp & Dohme Corporation ($1,870) |
| 2017 | $6,548 | 6 | Merck Sharp & Dohme Corporation ($6,548) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $40,862.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $14,007.50 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $115,187.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $28,167.50 | Research |
| Study: A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | ||||||
| 06/08/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $83,188.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 05/04/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $17,548.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $87.50 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $180.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $120.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $120.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $360.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $447.50 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $180.00 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 02/04/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase IIB 1L GBM Methylated nivo mono chemo RT | E.R. Squibb & Sons, L.L.C. | $343,118 | 4 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $156,050 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $83,363 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $32,806 | 4 |
| A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $28,168 | 1 |
About Dr. Steven Finden, M.D
Dr. Steven Finden, M.D is a Diagnostic Radiology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902822430.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Finden, M.D has received a total of $664,346 in payments from pharmaceutical and medical device companies, with $54,870 received in 2024. These payments were reported across 68 transactions from 3 companies. The most common payment nature is "" ($643,504).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Philadelphia, PA
- Active Since 07/15/2006
- Last Updated 12/16/2014
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1902822430
Products in Payments
- OPDIVO (Biological) $343,118
- KEYTRUDA (Biological) $20,843
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Philadelphia
Jill Langer, Md, MD
Diagnostic Radiology — Payments: $2.5M
Diagnostic Radiology $2.5M
Joan Prowda, Md, MD
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Lisa Jones, Md, MD
Diagnostic Radiology — Payments: $1.3M
Diagnostic Radiology $1.3M
Evan Siegelman, Md, MD
Diagnostic Radiology — Payments: $1.2M
Diagnostic Radiology $1.2M
Parvati Ramchandani, Md, MD
Diagnostic Radiology — Payments: $971,832
Diagnostic Radiology $971,832
Dr. Patrick O'kane, M.d, M.D
Diagnostic Radiology — Payments: $584,199
Diagnostic Radiology $584,199